



Alina Miruna Grecea-Bălaj

Date of birth: 11/11/1988 | Nationality: Romanian |

WORK EXPERIENCE

MEDICAL ONCOLOGY SPECIALIST - BREAST CANCER UNIT – ONCOLOGY INSTITUTE 'PROF DR I CHIRICUTA' – 11/2022 – Current – CLUJ-NAPOCA

MEDICAL ONCOLOGY SPECIALIST - THORACIC CANCER UNIT – GUSTAVE ROUSSY – 11/2021 – 10/2022 – PARIS, VILLEJUIF, FRANCE

PHD RESEARCH STUDENT – UNIVERSITY OF MEDICINE AND PHARMACY 'I. HATIEGANU' – 31/08/2019 – Current – CLUJ-NAPOCA , ROMANIA

MEDICAL ONCOLOGY SPECIALIST DITEP DEPARTMENT – GUSTAVE ROUSSY INSTITUTE – 30/04/2019 – 30/10/2019 – VILLEJUIF , FRANCE

RESIDENT PHYSICIAN IN MEDICAL ONCOLOGY – CANCER INSTITUTE 'PROF. I. CHIRICUTA' – 30/04/2018 – 18/01/2019 – CLUJ-NAPOCA, ROMANIA

RESIDENT PHYSICIAN IN MEDICAL ONCOLOGY – 'GUSTAVE ROUSSY' INSTITUTE – 30/04/2015 – 04/2018 – VILLEJUIF, PARIS, FRANCE

RESIDENT PHYSICIAN IN MEDICAL ONCOLOGY – CANCER INSTITUTE "PROF.I.CHIRICUTA" – 12/2013 – CLUJ-NAPOCA

Address: 34-36 Republicii street, 400015, Cluj-Napoca

MEDICAL VOLUNTEER DURING SUMMER PRACTICE – HASAN SADIKIN HOSPITAL – 07/2011 – 09/2011 – BANDUNG, INDONESIA

EDUCATION AND TRAINING

2013 – 2019 Cluj-Napoca, Romania

MEDICAL SPECIALIST IN MEDICAL ONCOLOGY Cancer Institute 'Prof. I. Chiricuta'

Address Republicii, 34-36, Cluj-Napoca, Romania

2006 – 2013 Cluj-Napoca, Romania

MEDICAL DOCTOR DEGREE University of Medicine and Pharmacy "Iuliu Hatieganu "

2002 – 2007 Cluj-Napoca, Romania

BACHELOR`S DEGREE "Gheorghe Sincai" Highschool

Philology fields (English, French, Latin, History)

LANGUAGE SKILLS

Mother tongue(s): **ROMANIAN**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
ENGLISH	C2	C2	C2	C2	C2
FRENCH	C1	C1	C1	C1	C1

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

SKILLS

Microsoft Word | Microsoft Excel | Microsoft Powerpoint | Microsoft Office | Google Drive

NETWORKS AND MEMBERSHIPS

Memberships

European Society of Medical Oncology
American Society of Clinical Oncology
Member of Romanian Society of Medical Oncology and Radiotherapy
Member of Medical Students Organization (auditor position), 2011-2013

PUBLICATIONS

Serum TNF - α , IL-10 and IL-2 Trajectories and Outcomes in NSCLC and Melanoma Under Anti-PD-1 Therapy: Longitudinal Real-World Evidence from a Single Center. *Current Issues in Molecular Biology*, Sep 2025, 47(9), 746. <https://doi.org/10.3390/cimb47090746>

Immune Cell-Cytokine Interplay in NSCLC and Melanoma: A Pilot Longitudinal Study of Dynamic Biomarker Interactions. *Immuno*. 5. [10.3390/immuno5030029](https://doi.org/10.3390/immuno5030029).

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. *OncoTargets and therapy*, 14, 5275-5291. <https://doi.org/10.2147/OTT.S283892>

Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease. *Cancers (Basel)*. 2022 Jun 13;14(12):2914. doi: [10.3390/cancers14122914](https://doi.org/10.3390/cancers14122914)

Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death Ligand 1 Blockade: A Case Discussion and Review of the Literature. *The Oncologist*, 24th of February 2020

'Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer. Published in [ascopubs.oru4ournal/po](https://ascopubs.org/journal/po), on the 6th of March 2019

SUBINVESTIGATOR IN CLINICAL TRIALS

Clinical trials - sub-investigator

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

ASTEFANIA: A phase III study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy

A trial to evaluate efficacy and safety of Ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer - NATALEE

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer - MONARCHE

Study CT-P6 3.2: A Phase 3, Double-Blind, Randomized, Parallel-Group, Active-Controlled Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Positive Early Breast Cancer

CERTIFICATIONS

'Diplôme universitaire de'immuno-oncologie -DUIO 2019/2020', Université Paris-Saclay

13.02.2026